Citations

Clear

959 citation(s) found for "Service, F J".

CNS manifestations in acute and chronic graft-versus-host disease
Lambert, Nicolas , Forte, Florence, Monseur, Justine, Raus, Nicole, Shultz, Carl , Balaguer‐Roselló, Aitana , Gil‐Perotín, Sara , Brijs, Jan , Chauvet, Paul , Carré, Martin , Dulămea, Adriana Octaviana , Salmenniemi, Urpu , Nguyen, Stéphanie , Smallbone, Portia , González‐Vicent, Marta , Willems, Évelyne, Baron, Frédéric , Servais, Sophie , Béguin, Yves , Maquet, Pierre , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Dulamea, Adriana Octaviana, Tănase, Alina , Salmenniemi, Urpu, Butera, Sara , Piekarska, Agnieszka , Davies, J. M., Labussière-Wallet, Hélène, D’Aveni, Maud , Willems, Evelyne, Gil-Perotín, Sara , Chalandon, Yves , Santoro, Jonathan D , Servais, Sophie , Lambert, Nicolas , Moussaoui, Majdouline El , Raus, Nicole, Polushin, Alexey Yu. , Michonneau, David , Hogan, William J. , Gavriilaki, Maria , Chalandon, Yves , Duminuco, Andrea , Ram, Ron , García‐Cadenas, Irene , Porto, Gaetana , Santoro, Jonathan D. , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Skiba, Iaroslav B. , Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Sakellari, Ioanna , Dulamea, Adriana Octaviana, Chantepie, Sylvain , Salmenniemi, Urpu, Loschi, Michael L. , Martino, Massimo , Mensah‐Glanowska, Patrycja , Labussière-Wallet, Hélène, Hamadani, Mehdi , Willems, Evelyne

Mayo Clinic

Brain | October 23, 2024 | Volume: 148 | Issue: 4 | Pages: 1122-1133

10.1093/brain/awae340 | PMID 39442000 Get It

Abstract Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this multicentre retrospective study, we analysed the clinical, biological, radiological and histopathological characteristics, as well as the clinical course of 66 patients diagnosed with possible CNS-GvHD (pCNS-GvHD), selected by predetermined diagnostic criteria. Results were then contrasted depending on whether pCNS-GvHD onset occurred before or after Day 100 following allogeneic haematopoietic stem cell transplantation (allo-HSCT). The median time between allo-HSCT and pCNS-GvHD onset was 149 days (interquartile range25–75 48–321), and pCNS-GvHD onset occurred before Day 100 following transplantation in 44% of patients. The most frequent findings at presentation were cognitive impairment (41%), paresis (21%), altered consciousness (20%), sensory impairment (18%) and headache (15%). Clinical presentation did not significantly differ between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Brain MRI found abnormalities compatible with the clinical picture in 57% of patients, while CT detected abnormalities in only 7%. Seven patients had documented spinal cord MRI abnormalities, all of them with pCNS-GvHD occurring after Day 100 following transplantation. In the CSF, the white blood cell count was increased in 56% of the population (median 18 cells/μl). Histopathological analyses were performed on 12 specimens and were suggestive of pCNS-GvHD in 10. All compatible specimens showed parenchymal and perivascular infiltration by CD3+ and CD163+ cells. Immunosuppressive therapy was prescribed in 97% of patients, achieving complete clinical response in 27%, partial improvement in 47% and stable disease in 6%. Response to immunosuppressive therapy did not differ significantly between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Clinical relapse was observed in 31% of patients who initially responded to treatment. One-year overall survival following pCNS-GvHD onset was 41%. Onset before Day 100 following haematopoietic stem cell transplantation [hazard ratio with 95% confidence interval: 2.1 (1.0–4.5); P = 0.041] and altered consciousness at initial presentation [3.0 (1.3–6.7); P = 0.0077] were associated with a reduced 1-year overall survival probability. Among surviving patients, 61% had neurological sequelae. This study supports that immune-mediated CNS manifestations may occur following allo-HSCT. These can be associated with both acute and chronic GvHD and carry a grim prognosis. The clinical presentation as well as the radiological and biological findings appear variable.
An Integrated Approach to Improving Itinerary Completion in Coordinated Care Networks
Liu, Yiqiu , Oyen, Mark P. Van , Hucshka, Todd, Shi, Pengyi , Helm, Jonathan Eugene , Ying, Lei

Mayo Clinic

Manufacturing & Service Operations Management | October 15, 2024 | Volume: 27 | Issue: 1 | Pages: 21-39

10.1287/msom.2022.0649 Get It

Problem definition: Coordinated care network (CCN) is a burgeoning paradigm where patients’ diagnosis and treatment plans are developed based on collaboration between multiple, colocated medical specialties to holistically address patients’ health needs. A primary performance metric for CCNs is how quickly patients can complete their itinerary of appointments at multiple medical services in the network. Rapid completion is critical to care delivery but also presents a major operational challenge. Because information about a patient’s condition and treatment options evolves over the course of the itinerary, care paths are not known a priori. Thus, appointments (except for the first one) cannot be reserved in advance, which may result in significant delays if capacity is not allocated properly. Methodology/results: We study capacity allocation for the patient’s first (root) appointment as the primary operational lever to achieve rapid itinerary completion in CCNs. We develop a novel queueing-based analytical framework to optimize this root appointment allocation, maximizing the proportion of patients completing care by prespecified deadlines. Our framework accounts for the complex interactions among all patients in the network through the blocking process, which contrasts with conventional siloed planning. We provide an exact characterization of the itinerary time and develop a mean-field approximation with convergence guarantees that permits tractable solutions for large-scale network problems. In a simulation case study of Mayo Clinic, our solution improves on-time completion from 60% under the current plan to more than 93%. Managerial implications: We demonstrate that root appointment allocation is a multifaceted problem and that ignoring any of those facets can lead to poor performance. Simultaneously accounting for all of these complexities makes manual template design or traditional optimization methods inadequate, highlighting the significance of our integrated approach. Supplemental Material: The online appendix is available at https://doi.org/10.1287/msom.2022.0649 .
Cardiac troponin elevation and mortality in takotsubo syndrome: New insights from the international takotsubo registry
Stähli, Barbara E. , Schindler, Matthias , Schweiger, Victor , Cammann, Victoria L. , Szawan, Konrad A. , Niederseer, David , Würdinger, Michael , Schönberger, Alexander, Schönberger, Maximilian, Koleva, Iva, Mercier, Julien C., Petkova, Vanya, Mayer, Silvia, Gili, Sebastiano , Franke, Jennifer , Meder, Benjamin , Jaguszewski, Miłosz, Knorr, Maike, Jansen, Thomas , Lewinski, Dirk von , Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Roffi, Marco , Wolfrum, Mathias , Fischer, Thomas, Vasankari, Tuija , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Gilyarov, Mikhail , Akın, İbrahim , Poledníková, Karolína, Massoomi, Michael , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio , Ishibashi, Iwao, Himi, Toshiharu, Din, Jehangir , Rihal, Charanjit S. , Liu, Kan , Jörg, Lucas, Rickli, Hans , Böhm, M., Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Rottbauer, Wolfgang , Budnik, Monika , Opolski, Grzegorz , Thiele, Holger, Kong, William, Dalakoti, Mayank , Imori, Yoichi , Liberale, Luca , Münzel, Thomas , Bax, J. J., Ghadri, Jelena R. , Vece, Davide Di , Templin, Christian , Budnik, Monika , Roffi, Marco , Liberale, Luca , Montecucco, Fabrizio , von Lewinski, Dirk , Tschöpe, Carsten , Meyer, Philippe , Bilato, Claudio , Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Neuhaus, Michael, Noutsias, Michel , D’Ascenzo, Fabrizio, Dichtl, Wolfgang , Cuneo, Alessandro , Köenig, Wolfgang , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Airaksinen, Juhani , Napp, L. Christian , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , El‐Battrawy, Ibrahim , Toušek, Petr , Winchester, David E. , Gałuszka, Jan , Ukena, Christian , Poglajen, Gregor , Kato, Ken , Al‐Shammari, Ali Saad , Prasad, Abhiram , Rihal, Charanjit S. , Schulze, Paul Christian , Bianco, Matteo , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Pieske, Burkert , Schunkert, Heribert , Thiele, Holger , Bauersachs, Johann , Horowitz, John D. , Mario, Carlo Di , Crea, Filippo , Luescher, T F , Ruschitzka, Frank T.

Mayo Clinic

European Journal of Clinical Investigation | October 14, 2024 | Volume: 54 | Issue: 12 | Pages: No page available

10.1111/eci.14317 | PMID 39397275 Get It

AbstractBackgroundThe clinical relevance of cardiac troponin (cTn) elevation in takotsubo syndrome (TTS) remains uncertain. The present study sought to investigate the role of cardiac troponin (cTn) elevations in mortality prediction of patients with Takotsubo syndrome (TTS).MethodsPatients enrolled in the International Takotsubo (InterTAK) Registry from January 2011 to February 2020 with available data on peak cTn levels were included in the analysis. Peak cTn levels during the index hospitalization were used to define clinically relevant myocardial injury. The threshold at which clinically relevant myocardial injury drives mortality at 1 year was identified using restricted cubic spline analysis.ResultsOut of 2′938 patients, 222 (7.6%) patients died during 1‐year follow‐up. A more than 28.8‐fold increase of cTn above the upper reference limit was identified as threshold for clinically relevant myocardial injury. The presence of clinically relevant myocardial injury was significantly associated with an increased risk of mortality at 5 years (adjusted HR 1.58, 95% CI 1.18–2.12, p =.002). Clinically relevant myocardial injury was related to an increased 5‐year mortality risk in patients with apical TTS (adjusted HR 1.57, 95% CI 1.21–2.03, p =.001), in presence of physical stressors (adjusted HR 1.60, 95% CI 1.22–2.11, p =.001), and in absence of emotional stressors (adjusted HR 1.49, 95% CI, 1.17–1.89, p =.001).ConclusionThis study for the first time determined a troponin threshold for the identification of TTS patients at excess risk of mortality. These findings advance risk stratification in TTS and assist in identifying patients in need for close monitoring and follow‐up.
Conservative management of brain arteriovenous malformations: results of the prospective observation registry of a pragmatic trial
Gentric, Jean-Christophe, Heppner, Jonathan, Lopez, Camille, Jabre, Roland , Bojanowski, Michel W. , Chaalala, Chiraz , Januel, Anne-Christine, Sabatier, Jean-François, Desal, Hubert, Roualdes, Vincent , Alias, Quentin , Derrey, Stéphane , Gaberel, Thomas , Barbier, Charlotte , Barreau, Xavier , Anxionnat, René , Merlot, Isabelle, Nguyen, Thanh N., Abdalkader, Mohamad , Riva, Roberto, Troude, Lucas, Ollivier, Irène , Planty-Bonjour, Alexia, Chalumeau, Vanessa, Naggara, Olivier, Lefevre, Pierre-Henri, Corre, Marine Le, Carlson, Andrew P. , Thines, Laurent, Findlay, J. Max, Chabert, Emmanuel , Zehr, Justine , Klink, Ruby , Viard, Geraldine, Magro, Elsa, _, _, Raymond, Jean , Chow, Michael M. C., Findlay, J. Max , Lesiuk, Howard , Drake, Brian , Santos, Marlene dos, Lopez, Camille, Ognard, Julien, Seizeur, Romuald, Pradier, Olivier, Boursier, Romain, Thillays, F. , Januel, Anne-Christine , Sabatier, Jean-François, Calvière, Lionel , Gauvrit, Jean‐Yves , Eugene, François, Boucherit, Julien , Lecouillard, Isabelle, Briens, Aurélien, Ronzière, Thomas , Trystram, D. , Naggara, Olivier , Emery, Évelyne , Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Bougaci, Nassim , Bracard, Serge, Civit, Thierry, Bernier‐Chastagner, Valérie , Penchet, Guillaume, Gimbert, Edouard, Huchet, Aymeri, Herbreteau, Denis , Bibi, Richard , Ifergan, Héloïse , Janot, Kévin, Brunel, Hervé, Roche, Pièrre-Hugues , Peyrière, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Boissonneau, Sébastien , Clarençon, Frédéric , Premat, Kévin, Boch, Anne‐Laure , Cornu, Philippe, Nouet, Aurélien , Costalat, Vincent , Gascou, Gregory, Riquelme, Carlos, Pop, Raoul, Proust, François, Cébula, H. , Spatola, Giorgio, Ikka, Léon , Ozanne, Augustin , Caroff, Jildaz , Rouchaud, Aymeric, Caire, François, Ricolfi, F. , Thouant, Pierre, Cao, Catherine, Mourier, Klaus-Luc, Farah, Walid, Silva, Luciana Alves Oliveira, Froio, Nayara de Lima, Mont’Alverne, Francisco J. A., Martins, Jose Luri, Miranda, Rodrigo Rivera, Rivera, Rodrigo , Ognard, Julien , Shotar, Eimad , Ognard, Julien , Darsaut, Tim E. , Iancu, Daniela , Roy, Daniel C. , Weill, Alain , Comby, Pierre‐Olivier , Roberge, David , Cognard, Christophe , Desal, Hubert , Ferré, Jean‐Christophe , Papagiannaki, Chrysanthi , Smajda, Stanislas , Aldéa, Sorin , Marnat, Gaultier , Jecko, Vincent , Dumot, Chloé , Riva, Roberto , Graillon, Thomas , Troude, Lucas , Kerleroux, Basile , Beaujeux, Rémy , Boulouis, Grégoire , Spelle, Laurent , Chalumeau, Vanessa , Lefèvre, Pierre-Henri , Corre, Marine Le, Shotar, Eimad , Biondi, Alessandra , Tawk, Rabih G. , Huynh, Thien , Fahed, Robert , Gévry, Guylaine , _, _, O'Kelly, Cian J , Rempel, Jeremy L , Santos, Marlene dos, Gentric, Jean‐Christophe , Lopez, Camille, Nonent, Michel , Aouni, Mourad Cheddad El , Timsit, Serge , Piotin, Michel , Blanc, Raphaël , Morandi, Xavier , Vannier, Stéphane , Rodriguez-Régent, Christine , Touzé, Emmanuel , Eker, Omer , Charbonnier, Guillaume , Gory, Benjamin , Velut, Stéphane , Sourour, Nader Antoine , Lenck, Stéphanie , Premat, Kévin , Bonafé, Alain , Dargazanli, Cyril , Gascou, Grégory , Corre, Marine Le, Gallas, Sophie , Mihalea, Cristian , Mounayer, Charbel , Thouant, Pierre , Nguyen, Thanh N. , Silva, Gisele Sampaio , Montalverne, Francisco Jose , Mendes, George Nilton Nunes

Mayo Clinic

Journal of Neurosurgery | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2024.5.jns24623 | PMID 39393100 Get It

OBJECTIVE Many patients recruited in the Treatment of Brain Arteriovenous Malformations Study (TOBAS) are managed conservatively. The aim of this study was to monitor what happened to those patients. METHODS TOBAS comprises two randomized controlled trials and multiple prospective registries. All patients with brain arteriovenous malformations (AVMs) can participate. This report concerns patients selected for conservative management. The primary trial outcome measure is related death or dependency (modified Rankin Scale [mRS] score > 2) at 10 years. Secondary outcomes include intracranial hemorrhages, nonhemorrhagic neurological events, and serious adverse events (SAEs). For this report, outcome results are presented using patient-years, Kaplan-Meier survival curves, and Cox log-rank tests. There was no blinding. RESULTS From June 2014 to May 2021, 1010 patients were recruited, of whom 498 (49%) were proposed the prospective observation registry. After exclusions, 434 (87%) patients remained for analysis. The majority of patients had unruptured AVMs (378/434 [87%]), of which 195 (52%) were low grade (Spetzler-Martin grade I or II). During a mean follow-up period of 3.2 years (total 1368 patient-years), the primary outcome occurred in 23 of 434 (5%) patients, corresponding to an incidence of 1.7 (95% CI 1.1–2.5) per 100 patient-years. For unruptured AVMs the incidence was 1.1 (95% CI 0.7–1.9) per 100 patient-years, and for low-grade unruptured AVMs it was 0.6 (95% CI 0.2–1.7) per 100 patient-years. Poor outcomes were more frequent in patients with a history of rupture (HR 5.6 [95% CI 2.4–13.0], p < 0.001), infratentorial AVMs (HR 2.9 [95% CI 1.1–7.3], p = 0.027), and age ≥ 55 years (HR 3.2 [95% CI 1.4–7.6], p = 0.007). Major intracranial hemorrhage occurred in 35 of 434 (8%) patients (incidence of 2.6 [95% CI 1.9–3.6] per 100 patient-years; 2.0 [95% CI 1.3–2.9] per 100 patient-years for unruptured AVMs and 1.3 [95% CI 0.6–2.6] per 100 patient-years for low-grade unruptured AVMs). Major AVM hemorrhages were more frequent in ruptured (HR 4.4 [95% CI 2.1–8.9], p < 0.001), large (HR 2.6 [95% CI 1.1–6.6], p = 0.039), and high-grade (HR 2.5 [95% CI 1.2–5.3], p = 0.013) AVMs and those with deep venous drainage (HR 2.1 [95% CI 1.1–4.2], p = 0.032). SAEs occurred in 48 of 434 (11%) patients (incidence of 3.6 [95% CI 2.7–4.8] per 100 patient-years). For unruptured AVMs the incidence was 2.8 (95% CI 2.0–4.0) per 100 patient-years, and for low-grade unruptured AVMs it was 1.8 (95% CI 1.0–3.2) per 100 patient-years. CONCLUSIONS Nearly half of TOBAS participants were observed. Rates of untoward neurological events were within expected boundaries.
Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis
Ullah, Waqas , Sandhyavenu, Harigopal , Taha, Amro , Gowda, Smitha Narayana , Mukhtar, Maryam , Polam, Aravind Reddy , Zahid, Salman , Fischman, David L. , Savage, Michael P. , Rao, Sunil V. , Reddy Polam, Aravind , Alkhouli, Mohamad , Mukhtar, Maryam , Rao, Sunil V , Fischman, David , Sandhyavenu, Harigopal , Alkhouli, Mohamad

Mayo Clinic

Journal of the American Heart Association | October 11, 2024 | Volume: 13 | Issue: 20 | Pages: No page available

10.1161/jaha.122.032490 | PMID 39392170 Get It

Background Optimal duration and choice of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention remain controversial. Methods and Results Digital databases (PubMed, Cochrane, and Embase) were queried to select all randomized controlled trials on a post–percutaneous coronary intervention population with acute coronary syndrome. Dual‐antiplatelet therapy (DAPT) with aspirin and clopidogrel for 12 months was compared with 4 major strategies: high‐potency, high‐ to low‐potency, low‐dose, and short‐duration DAPT. A network meta‐analysis was performed to compare the safety and efficacy of different antiplatelet strategies. This study was the second updated manuscript under the International Prospective Register of Systematic Review registration (CRD42021286552). Thirty‐two randomized controlled trials comprising 103 459 (51 750 experimental, 51 709 control) patients were included. Compared with DAPT with aspirin and clopidogrel for 12 months, high‐ to low‐potency DAPT (risk ratio [RR], 0.69 [95% CI, 0.52–0.92]) and aspirin+prasugrel containing DAPT for 12 months (RR, 0.84 [95% CI, 0.72–0.98]) had a significantly lower, whereas DAPT for 1 month followed by clopidogrel only (RR, 1.59 [95% CI, 1.06–2.39]) had a higher, incidence of major adverse cardiovascular events at 1 year (median follow‐up). Prasugrel (RR, 1.35 [95% CI, 1.09–1.66]) and ticagrelor (RR, 1.38 [95% CI, 1.17–1.62]) containing DAPT for 12 months had significantly higher rates, whereas high‐ to low‐potency DAPT (RR, 0.85 [95% CI, 0.63–1.15]) had no significant risk of major bleeding. Conclusions Aspirin and ticagrelor for 3 months, followed by aspirin and clopidogrel for the remaining duration, can be considered the optimal strategy for treating post–percutaneous coronary intervention patients with acute coronary syndrome because of a significantly reduced risk of major adverse cardiovascular events without increasing the risk of bleeding.
7790 A Non-interventional, Multinational, Phase IV Study to Evaluate the Long-Term Safety and Efficacy of Osilodrostat in Patients with Endogenous Cushing's Syndrome (LINC 6): 1-Year Real-World Interim Analysis
Feelders, Richard A. , Reincke, Martín , Tabarin, Antoine , Mouhaër, Jeannie Le, Stermenska, J, Maldonado, Mario, Bancos, Irina , Geer, Eliza B. , Castinetti, Frédéric , Fleseriu, Maria , Pivonello, Rosario , Biller, Beverly M. K.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.1098 Get It

Abstract Disclosure: I. Bancos: Advisory Board Member; Self; Adrenas, Diurnal, Neurocrine, Spruce, HRA Pharmaceuticals, Sparrow, Recordati Rare Diseases, Xeris, Novo Nordisk, AstraZeneca, Corcept. Consulting Fee; Self; Adrenas, Diurnal, Neurocrine, Spruce, HRA Pharmaceuticals, Sparrow, Recordati Rare Diseases, Xeris, Novo Nordisk, AstraZeneca, Corcept. Grant Recipient; Self; Recordati, HRA Pharmaceuticals. Other; Self; Adrenas, Diurnal, Neurocrine, Spruce, HRA Pharmaceuticals, Sparrow, Recordati Rare Diseases, Xeris, Novo Nordisk, AstraZeneca, Corcept. E.B. Geer: Advisory Board Member; Self; Recordati Rare Diseases. Consulting Fee; Self; Lundbeck, Crinetics, HRA Pharmaceuticals, Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals (Strongbridge). Grant Recipient; Self; Xeris Pharmaceuticals (Strongbridge), Corcept, Recordati Rare Diseases, Sparrow. F. Castinetti: Consulting Fee; Self; HRA Pharmaceuticals, Recordati. Grant Recipient; Self; HRA Pharmaceuticals, Recordati. R. Feelders: Advisory Board Member; Self; Recordati. Consulting Fee; Self; HRA Pharmaceuticals, Recordati. Grant Recipient; Self; Corcept Therapeutics. M. Fleseriu: Advisory Board Member; Self; Recordati Rare Diseases. Consulting Fee; Self; Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals (Strongbridge). Grant Recipient; Self; Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals (Strongbridge). R. Pivonello: Consulting Fee; Self; Corcept Therapeutics, Recordati, Crinetics Pharmaceuticals, H Lundbeck. Grant Recipient; Self; Recordati, Corcept Therapeutics, Xeris Pharmaceuticals (Strongbridge), Neurocrine Biosciences. M. Reincke: Advisory Board Member; Self; Recordati Rare Diseases. Consulting Fee; Self; Recordati Rare Diseases, HRA Pharmaceuticals, Lundbeck, Crinetics. Grant Recipient; Self; Recordati Rare Diseases, HRA Pharmaceuticals, Lundbeck, Crinetics. Speaker; Self; Recordati Rare Diseases, HRA Pharmaceuticals, Lundbeck, Crinetics. A. Tabarin: Advisory Board Member; Self; Recordati Rare Diseases. Consulting Fee; Self; H Lundbeck, Crinetics, HRA Pharmaceuticals, Recordati Rare Diseases. J. Le Mouhaër: Employee; Self; Recordati. J. Stermenska: Employee; Self; Recordati. M. Maldonado: Employee; Self; Recordati. B.M. Biller: Advisory Board Member; Self; Recordati Rare Diseases. Consulting Fee; Self; H Lundbeck, Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals (Strongbridge). Introduction: Osilodrostat, a potent oral 11β-hydroxylase inhibitor, provides control of cortisol production and improves outcomes in patients (pts), as shown by the clinical development program of Cushing’s disease (CD; Fleseriu M et al. Lancet Diabetes Endocrinol 2021;9:847-75) leading to EMA approval for Cushing’s syndrome (CS) and FDA approval for CD. The prospective LINC 6 study (NCT05382156) evaluates long-term safety and efficacy of osilodrostat in routine clinical practice over a 3-­year follow-up of CS pts. Here, we report 1-year interim data. Methods: Pts aged ≥18 years with endogenous CS are being enrolled in countries where osilodrostat is approved and available (including USA and Europe), irrespective of prior osilodrostat use. Treatment decisions and follow-up are at investigator discretion. The primary endpoint is incidence of osilodrostat-related adverse events (AEs) and serious AEs, focusing on AEs related to hypocortisolism, accumulation of adrenal hormone precursors, QT prolongation and pituitary tumor enlargement. Secondary endpoints include change in mean urinary free cortisol (mUFC), serum cortisol and late-night salivary cortisol (LNSC). Evaluation of biochemical parameters is recommended at baseline, months 1 and 3, and every 3 months thereafter, as available. AEs are recorded at baseline and each visit. Analyses are descriptive. We report change for pts with assessments at baseline and every 3 months. Results: Of 106 pts enrolled at the 1-year interim analysis, 94 were included in the safety population: CD, n=78; non-CD CS, n=16 (adrenal adenoma, n=3; adrenal hyperplasia, n=3; ectopic, n=9; other, n=1). Mean (SD) age was 53.2 years (12.7); 70.2% (n=66) were female. Median (min-max) osilodrostat exposure and dose were 5.5 months (0.1-13.9) and 5.0 mg/day (1.0-60.0). 29 pts reported 109 AEs; 12 pts reported 44 AEs that were considered treatment related. Overall, the most common (≥5%) AEs were asthenia and vomiting (both n=6/109; 5.5%); treatment-related AEs with highest frequency were vomiting and dizziness (both n=4/44; 9.1%). 7 AEs led to discontinuation in 4 pts; 5 AEs were considered osilodrostat related (nausea and vomiting in 1 pt; worsening hypertension, uncontrolled blood pressure and dizziness in another) and 2 were not (pituitary tumor surgery and right adrenalectomy). AEs related to hypocortisolism, accumulation of adrenal hormone precursors, QT prolongation and pituitary tumor enlargement occurred in 7 (7.4%), 4 (4.3%), 2 (2.1%) and 0 pts, respectively. At month 3, mUFC, serum cortisol and LNSC were normalized in 71.4% (n=10/14), 69.2% (n=18/26) and 50.0% (n=7/14) of pts. Conclusions: Results from this real-world clinical setting show that osilodrostat is generally well tolerated and provides early improvements in mUFC and LNSC in pts with endogenous CS, building on evidence from the previous randomized, controlled trials LINC 3 and LINC 4. Presentation: 6/3/2024
Workplace Violence Against Emergency Medical Services (EMS): A Prospective 12-Month Cohort Study Evaluating Prevalence and Risk Factors Within a Large, Multistate EMS Agency
Bellolio, Fernanda , Buck, B., Liedl, Chad P., Stuhr, Dayne D., Buffum, Mykell Ryan, Clements, Casey M. , McGuire, Sarayna S. , Buck, Bradley J, Bellolio, M Fernanda , Buck, Bradley J., Mullan, Aidan F.

Mayo Clinic

Prehospital Emergency Care | October 2, 2024 | Volume: 29 | Issue: 6 | Pages: 760-767

10.1080/10903127.2024.2411020 | PMID 39356230 Get It

ASHP and ASHP Foundation Pharmacy Forecast 2025: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
Hoffman, James M. , Tichy, Eric M. , Shea, Suzanne, Sanborn, Michael, Fox, Erin R. , Torrise, Virginia, Abourjaily, Paul , Cunningham, Francesca , Schweitzer, Pamela, Nelson, Scott D. , Stump, Lisa S, Castro, Harvey, Nesbit, Todd, Scott, Christopher M., Tichy, Eric, DiPiro, Joseph T. , Shea, Suzanne, Hung, Anna , Watanabe, Jonathan Hirohiko , Stump, Lisa S. , Castro, Harvey

Mayo Clinic

American Journal of Health-System Pharmacy | September 27, 2024 | Volume: 82 | Issue: 2 | Pages: 17-47

10.1093/ajhp/zxae280 | PMID 39657700 Get It

Abstract Purpose The 2025 ASHP Pharmacy Forecast report is written to identify and contextualize emerging trends that will influence healthcare, health systems, and the pharmacy profession. It provides recommendations to inform strategic planning that should prompt action by pharmacists and health-system leaders. Methods Drawing on the “wisdom of crowds” concept, a survey was constructed by an advisory committee with 6 themes, each with 7 focused statements and a seventh theme on preparedness (54 survey items in total). A survey panel of 321 pharmacy leaders was purposefully designed to capture opinions from a wide range of pharmacists across the United States. Panelists were asked to consider the likelihood of the statements occurring in the next 5 years as being likely, somewhat likely, somewhat unlikely, or very unlikely to occur. Forecast panelists also assessed health systems’ preparedness (from very unprepared to very prepared) for 12 of the statements. Results The 6 survey themes identified were The Business of Healthcare: Challenges in Health-System Pharmacy, Managing Ultra-High-Cost Drugs, Addressing the Gap in Primary Care, Whole Person Health, Navigating Generative Artificial Intelligence: Opportunity and Risk, and Stabilizing the Pharmacy Workforce. The survey was completed by 269 respondents, yielding an 84% response rate. Descriptive statistics of the survey results were provided to chapter authors to inform commentary and strategic recommendations for each theme. Conclusion The Pharmacy Forecast provides insights on large-scale, long-term trends that will influence healthcare and the pharmacy profession over the years ahead. Insight from the report can stimulate strategic thinking and provides a starting point to proactively position leaders, their teams, and departments for potential future trends.
Germline mutations in a G protein identify signaling cross-talk in T cells
Ham, Hyoungjun , Jing, Huie , Lamborn, Ian T. , Kober, M. , Anderson, David E. , Druey, Kirk M. , Mandl, Judith N. , Isidor, Bertrand , Freeman, Alexandra F. , Ganesan, Sundar , Karsak, Meliha , Mustillo, Peter , Teo, Juliana , Zolkipli‐Cunningham, Zarazuela , Lecoquierre, François , Schmid, Jana Pachlopnik , Kuhns, Douglas B. , Xu, Xuehua , Al–Herz, Waleed , Terhal, Paulien A., Muurinen, Mari , Barlogis, Vincent , Danielson, Jeffrey J. , Stewart, Helen , Rading, Sebastian, Keren, Boris , Pfundt, Rolph , Potocki, Lorraine , Olivier, Kenneth N., Faivre, Laurence , Wong, Melanie , Puel, Anne , Chou, Janet , Tusseau, Maud, Moutsopoulos, Niki M. , Matthews, Helen, Simons, Cas , Fink, Danielle , Kong, Heidi H. , Kabát, Juraj , Kim, Woo Sung , Bierhals, Tatjana , Meguro, Kazuyuki , Gu, Jingwen , Stoddard, Jennifer , Banos-Pinero, Benito, Slack, Maria A., Trivellin, Giampaolo , Mazel, Benoît , Li, Samuel T. , Watts, Val J. , Rodriguez-Quevedo, Maria F. , Bruel, Ange‐Line , Lehalle, Daphné , Torres, Daniel , Sullivan, Kathleen E. , Duffourd, Yannis, Similuk, Morgan , Blanc, Pierre , Jin, Tian, Geha, Raif S., Casanova, Jean‐Laurent , Mäkitie, Outi , Edery, Patrick , Germain, Ronald N. , Billadeau, Daniel D. , Zhang, Yu , Lenardo, Michael J. , Kober, Megan M , Koval, Alexey , Anderson, D Eric , Druey, Kirk M , Mandl, Judith N , Isidor, Bertrand , Ferreira, Carlos R , Freeman, Alexandra F , Karsak, Meliha , Mustillo, Peter J , Teo, Juliana , Chatron, Nicolas , Lecoquierre, Francois , Oler, Andrew J , Schmid, Jana Pachlopnik , Kuhns, Douglas B , Xu, Xuehua , Hauck, Fabian , Al-Herz, Waleed , Wagner, Matias , Terhal, Paulien A , Muurinen, Mari , Barlogis, Vincent , Loid, Petra , Keren, Boris , Pfundt, Rolph , Zarember, Kol A , Vill, Katharina , Olivier, Kenneth N , Lesca, Gaetan , Faivre, Laurence , Puel, Anne , Chou, Janet , Moutsopoulos, Niki M , Simons, Cas , Soldatos, Ariane , Masle-Farquhar, Etienne , Pittaluga, Stefania , Brink, Robert , Kong, Heidi H , Kabat, Juraj , Bierhals, Tatjana , Hsu, Amy P. , Gu, Jingwen , Trivellin, Giampaolo , Mazel, Benoît , Soomann, Maarja , Li, Samuel , Watts, Val J , Stratakis, Constantine A , Rodriguez-Quevedo, Maria F , Bruel, Ange-Line , Lipsanen-Nyman, Marita , Saultier, Paul , Lehalle, Daphne , Torres, Daniel , Barbarot, Sébastien , Neu, Axel , Similuk, Morgan N , McWalter, Kirsty , Blanc, Pierre , Bézieau, Stéphane , Geha, Raif S , Casanova, Jean Laurent , Makitie, Outi M , Edery, Patrick , Christodoulou, John , Germain, Ronald N , Goodnow, Christopher C , Sakmar, Thomas P , Billadeau, Daniel D , Kury, Sebastien , Katanaev, Vladimir L , Zhang, Yu , Lenardo, Michael J , Su, Helen C , Berchiche, Yamina A. , Wagner, Matias , Cruz, Phillip , Lesca, Gaëtan , Tusseau, Maud , Taft, Ryan J. , Pittaluga, Stefania , Baños-Piñero, Benito, Stratakis, Constantine A. , Jain, Rashmi, Bezieau, Stéphane , Jin, Tian , Kubisch, Christian , Küry, Sébastien , Su, Helen C.

Mayo Clinic

Science | September 19, 2024 | Volume: 385 | Issue: 6715 | Pages: No page available

10.1126/science.add8947 | PMID 39298586 Get It

Humans with monogenic inborn errors responsible for extreme disease phenotypes can reveal essential physiological pathways. We investigated germline mutations in GNAI2 , which encodes G αi2 , a key component in heterotrimeric G protein signal transduction usually thought to regulate adenylyl cyclase–mediated cyclic adenosine monophosphate (cAMP) production. Patients with activating G αi2 mutations had clinical presentations that included impaired immunity. Mutant G αi2 impaired cell migration and augmented responses to T cell receptor (TCR) stimulation. We found that mutant G αi2 influenced TCR signaling by sequestering the guanosine triphosphatase (GTPase)–activating protein RASA2, thereby promoting RAS activation and increasing downstream extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT S6 signaling to drive cellular growth and proliferation.